AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US ...

AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...

The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...

Neurogene shares tumbled 35% last night after it disclosed that a pediatric patient with Rett syndrome experienced a severe ...

Sheena Berry, healthcare analyst at Quilter Cheviot, said the Chinese authorities' probe into AstraZeneca had rocked the ...

For the week ended Nov. 8, 11 stocks dropped into undervalued territory, meaning their Morningstar Ratings changed to 4 or 5 ...

Covid vaccines left Aussie mother-of-two Ellie Sutton in such agony she 'prayed for death' and has considered euthanasia.

DNA synthesis platform developer joins de novo designer in latest of three partnerships recently launched or advanced.

Weighing on London, AstraZeneca fell 8.2%, losing its top spot as the most valuable company on the FTSE 100 to oil major Shell in the process. The Cambridge-based pharmaceuticals firm fell back ...